You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDigoxin
Accession NumberDB00390  (APRD00098)
TypeSmall Molecule
GroupsApproved
DescriptionA cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Structure
Thumb
Synonyms
12beta-Hydroxydigitoxin
12β-hydroxydigitoxin
4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
Digazolan
Digossina
Digoxin
Digoxina
Digoxine
Digoxinum
Lanadicor
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DigoxinTablet.125 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-01-14Not applicableUs
DigoxinTablet.125 mg/1OralUnit Dose Services2014-01-14Not applicableUs
DigoxinSolution.05 mg/mLOralAtlantic Biologicals Corps2004-08-26Not applicableUs
DigoxinTablet.125 mg/1OralCardinal Health2014-01-14Not applicableUs
DigoxinSolution.05 mg/mLOralWest Ward Pharmacueticals Corp.2004-08-26Not applicableUs
DigoxinTablet.125 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
DigoxinTablet.125 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
DigoxinTablet.125 mg/1OralREMEDYREPACK INC.2016-09-12Not applicableUs
DigoxinTablet.25 mg/1OralPar Pharmaceutical Inc.2014-01-14Not applicableUs
DigoxinSolution.05 mg/mLOralPrecision Dose Inc.2012-05-04Not applicableUs
DigoxinTablet.25 mg/1OralREMEDYREPACK INC.2016-09-21Not applicableUs
DigoxinTablet.125 mg/1OralPar Pharmaceutical Inc.2014-01-14Not applicableUs
DigoxinTablet.25 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
DigoxinTablet.25 mg/1OralNu Care Pharmaceuticals, Inc.2014-01-14Not applicableUs
Digoxin Injection C.S.D.Liquid0.25 mgIntramuscular; IntravenousSandoz Canada Incorporated1994-12-31Not applicableCanada
LanoxinTablet125 ug/1OralREMEDYREPACK INC.2013-03-042016-03-31Us
LanoxinTablet.0625 mg/1OralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
LanoxinTablet.25 mg/1OralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
LanoxinTablet125 ug/1OralRx Pak Division Of Mc Kesson Corporation1984-09-14Not applicableUs
LanoxinTablet0.0625 mgOralPharmascience Inc2001-06-222016-11-24Canada
LanoxinTablet.125 mg/1OralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
LanoxinTablet.0625 mg/1OralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
LanoxinTablet.125 mg/1OralCardinal Health2012-09-30Not applicableUs
LanoxinInjection, solution250 ug/mLIntramuscular; IntravenousCovis Pharmaceuticals, Inc.2013-02-15Not applicableUs
LanoxinTablet0.125 mgOralPharmascience Inc2001-03-162016-11-24Canada
LanoxinTablet125 ug/1OralCardinal Health1997-09-30Not applicableUs
LanoxinTablet250 ug/1OralCardinal Health1997-09-30Not applicableUs
LanoxinTablet.125 mg/1OralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
LanoxinTablet.1875 mg/1OralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
LanoxinTablet.25 mg/1OralCardinal Health2012-09-30Not applicableUs
LanoxinInjection, solution100 ug/mLIntramuscular; IntravenousCovis Pharmaceuticals, Inc.2013-01-14Not applicableUs
LanoxinTablet0.25 mgOralPharmascience Inc2001-03-162016-11-24Canada
LanoxinInjection, solution250 ug/mLIntramuscular; IntravenousCardinal Health1985-10-01Not applicableUs
LanoxinTablet125 ug/1OralCardinal Health1997-09-30Not applicableUs
LanoxinTablet.1875 mg/1OralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
LanoxinTablet.25 mg/1OralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
LanoxinTablet250 ug/1OralPd Rx Pharmaceuticals, Inc.1984-07-02Not applicableUs
Lanoxin Elx 0.05mg/ml PediatricLiquid.05 mgOralGlaxo Wellcome Inc.1956-12-312003-07-31Canada
Lanoxin Inj 0.05mg/ml PediatricLiquid.05 mgIntramuscular; IntravenousGlaxo Wellcome Inc.1963-12-312001-08-02Canada
Lanoxin Inj 0.25mg/mlLiquid.25 mgIntramuscular; IntravenousGlaxo Wellcome Inc.1955-12-312001-08-02Canada
Lanoxin Tab 0.0625mgTablet.0625 mgOralGlaxo Wellcome Inc.1987-12-312001-08-02Canada
Lanoxin Tab 0.125mgTablet.125 mgOralGlaxo Wellcome Inc.1971-12-312001-08-02Canada
Lanoxin Tab 0.25mgTablet.25 mgOralGlaxo Wellcome Inc.1936-12-312001-08-02Canada
Novo-digoxin Tab 0.25mgTablet.25 mgOralNovopharm Limited1966-12-312004-11-05Canada
Pediatric Digoxin Injection C.S.D.Liquid0.05 mgIntramuscular; IntravenousSandoz Canada Incorporated1994-12-31Not applicableCanada
PMS-digoxinTablet0.0625 mgOralPharmascience Inc2006-06-212016-10-28Canada
PMS-digoxinTablet0.125 mgOralPharmascience Inc2006-06-212016-10-28Canada
PMS-digoxinTablet0.25 mgOralPharmascience Inc2006-06-212016-10-28Canada
ToloxinTablet0.125 mgOralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
ToloxinTablet0.250 mgOralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
ToloxinSolution0.05 mgOralPendopharm Division Of De Pharmascience Inc2001-06-01Not applicableCanada
ToloxinTablet0.0625 mgOralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-digoxinTablet0.25 mgOralApotex Inc2006-06-22Not applicableCanada
Apo-digoxinTablet0.125 mgOralApotex Inc2006-06-22Not applicableCanada
Apo-digoxinTablet0.0625 mgOralApotex Inc2006-06-22Not applicableCanada
DigitekTablet.125 mg/1OralMylan Pharmaceuticals Inc.2014-11-17Not applicableUs
DigitekTablet.125 mg/1OralMylan Institutional Inc.2015-05-06Not applicableUs
DigitekTablet.25 mg/1OralMylan Pharmaceuticals Inc.2014-11-17Not applicableUs
DigitekTablet.25 mg/1OralMylan Institutional Inc.2015-05-06Not applicableUs
DigoxTablet125 ug/1OralProficient Rx LP2002-07-26Not applicableUs
DigoxTablet250 ug/1OralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
DigoxTablet125 ug/1OralCarilion Materials Management2002-07-26Not applicableUs
DigoxTablet250 ug/1OralREMEDYREPACK INC.2013-03-052016-04-05Us
DigoxTablet250 ug/1OralCarilion Materials Management2002-07-26Not applicableUs
DigoxTablet250 ug/1OralAidarex Pharmaceuticals LLC2002-07-26Not applicableUs
DigoxTablet125 ug/1OralLannett Company, Inc.2002-07-26Not applicableUs
DigoxTablet125 ug/1OralLake Erie Medical DBA Quality Care Products LLC2002-07-26Not applicableUs
DigoxTablet250 ug/1OralREMEDYREPACK INC.2015-12-30Not applicableUs
DigoxTablet.125 mg/1OralSt Marys Medical Park Pharmacy2013-05-02Not applicableUs
DigoxTablet125 ug/1OralTYA Pharmaceuticals2002-07-26Not applicableUs
DigoxTablet250 ug/1OralLannett Company, Inc.2002-07-26Not applicableUs
DigoxTablet250 ug/1OralPd Rx Pharmaceuticals, Inc.2002-07-26Not applicableUs
DigoxTablet125 ug/1OralMc Kesson Contract Packaging2012-09-28Not applicableUs
DigoxinTablet125 ug/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
DigoxinTablet250 ug/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-26Not applicableUs
DigoxinTablet250 ug/1OralWest Ward Pharmaceuticals Corp2007-10-30Not applicableUs
DigoxinTablet125 ug/1OralAmerican Health Packaging2014-09-23Not applicableUs
DigoxinTablet250 ug/1OralJerome Stevens Pharmaceuticals, Inc.2002-07-26Not applicableUs
DigoxinTablet125 ug/1OralCardinal Health2011-07-01Not applicableUs
DigoxinTablet125 ug/1OralA S Medication Solutions Llc2007-10-30Not applicableUs
DigoxinTablet.125 mg/1OralREMEDYREPACK INC.2011-07-20Not applicableUs
DigoxinTablet250 ug/1OralUnit Dose Services2002-07-26Not applicableUs
DigoxinInjection250 ug/mLIntramuscular; IntravenousGeneral Injecatables & Vaccines, Inc2010-07-01Not applicableUs
DigoxinTablet250 ug/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-30Not applicableUs
DigoxinTablet125 ug/1OralSun Pharmaceutical Industries, Inc.2015-02-17Not applicableUs
DigoxinTablet250 ug/1OralImpax Generics2009-07-20Not applicableUs
DigoxinTablet125 ug/1OralA S Medication Solutions2002-07-26Not applicableUs
DigoxinInjection, solution250 ug/mLIntramuscular; Intravenous; ParenteralSandoz Inc2003-08-21Not applicableUs
DigoxinTablet125 ug/1Oralbryant ranch prepack2007-10-30Not applicableUs
DigoxinInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp.1975-10-24Not applicableUs
DigoxinTablet250 ug/1OralA S Medication Solutions2009-07-20Not applicableUs
DigoxinTablet125 ug/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
DigoxinTablet250 ug/1OralCardinal Health2011-07-01Not applicableUs
DigoxinTablet250 ug/1OralAmerican Health Packaging2014-09-22Not applicableUs
DigoxinTablet.25 mg/301OralNorthwind Pharmaceuticals2014-05-16Not applicableUs
DigoxinTablet250 ug/1OralA S Medication Solutions Llc2007-10-30Not applicableUs
DigoxinInjection.25 mg/mLIntramuscular; IntravenousCardinal Health2011-06-28Not applicableUs
DigoxinTablet250 ug/1OralUnit Dose Services2015-02-17Not applicableUs
DigoxinTablet.125 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-30Not applicableUs
DigoxinTablet250 ug/1OralSun Pharmaceutical Industries, Inc.2015-02-17Not applicableUs
DigoxinTablet125 ug/1OralREMEDYREPACK INC.2014-10-08Not applicableUs
DigoxinTablet125 ug/1OralA S Medication Solutions2002-07-26Not applicableUs
DigoxinTablet250 ug/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
DigoxinTablet125 ug/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
DigoxinTablet250 ug/1Oralbryant ranch prepack2007-10-30Not applicableUs
DigoxinInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp.1975-10-24Not applicableUs
DigoxinTablet125 ug/1OralUnit Dose Services2015-02-17Not applicableUs
DigoxinTablet.125 mg/301OralNorthwind Pharmaceuticals2014-05-16Not applicableUs
DigoxinTablet125 ug/1OralCardinal Health2009-12-01Not applicableUs
DigoxinTablet125 ug/1OralNorthstar Rx LLC2016-09-12Not applicableUs
DigoxinTablet250 ug/1OralPhysicians Total Care, Inc.2000-08-21Not applicableUs
DigoxinTablet125 ug/1OralMc Kesson Contract Packaging2011-10-11Not applicableUs
DigoxinTablet125 ug/1OralCardinal Health2009-06-10Not applicableUs
DigoxinTablet125 ug/1OralDEPT HEALTH CENTRAL PHARMACY2008-05-01Not applicableUs
DigoxinTablet125 ug/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-26Not applicableUs
DigoxinTablet125 ug/1OralWest Ward Pharmaceuticals Corp2007-10-30Not applicableUs
DigoxinTablet250 ug/1OralCardinal Health2009-06-10Not applicableUs
DigoxinTablet250 ug/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
DigoxinTablet250 ug/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
DigoxinTablet125 ug/1OralUnit Dose Services2002-07-26Not applicableUs
DigoxinTablet125 ug/1OralREMEDYREPACK INC.2014-01-302016-04-05Us
DigoxinTablet125 ug/1OralImpax Generics2009-07-20Not applicableUs
DigoxinTablet250 ug/1OralNorthstar Rx LLC2016-09-12Not applicableUs
DigoxinTablet125 ug/1OralPhysicians Total Care, Inc.1992-09-22Not applicableUs
DigoxinTablet125 ug/1OralJerome Stevens Pharmaceuticals, Inc.2002-07-26Not applicableUs
DigoxinTablet125 ug/1OralPd Rx Pharmaceuticals, Inc.2002-07-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AgoxinAristopharma
CardiacinCenter
CardiogoxinMedipharma
CardioxinOboi
CardoxinNot Available
CeloxinCelon
CentoxinOpsonin
Digacinmibe
Digocard-GKlonal
DigoxinaGlaxoSmithKline
EudigoxTeofarma
LanacordinKern
LanacristNot Available
LanicorRoche
LanoxicapsNot Available
LenoxinGlaxoSmithKline
Brand mixturesNot Available
SaltsNot Available
Categories
UNII73K4184T59
CAS number20830-75-5
WeightAverage: 780.9385
Monoisotopic: 780.429606756
Chemical FormulaC41H64O14
InChI KeyLTMHDMANZUZIPE-PUGKRICDSA-N
InChI
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[[email protected]](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](O)[[email protected]](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
Pharmacology
IndicationFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
Structured Indications
PharmacodynamicsDigoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionDigoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1ProteinyesNot AvailableHumanP05023 details
Related Articles
AbsorptionAbsorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets).
Volume of distributionNot Available
Protein binding25%
Metabolism

Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.

SubstrateEnzymesProduct
Digoxin
Not Available
3 b-digoxigeninDetails
Digoxin
Not Available
3-keto-digoxigeninDetails
Route of eliminationFollowing intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine.
Half life3.5 to 5 days
ClearanceNot Available
ToxicityToxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline.Experimental
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDigoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolDigoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideDigoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-DichloroisocoumarinThe serum concentration of Digoxin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-Dihydroxybenzoic AcidDigoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Digoxin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
5,10-Dideazatetrahydrofolic AcidDigoxin may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineDigoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineDigoxin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineDigoxin may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneDigoxin may decrease the cardiotoxic activities of Abiraterone.Approved
ABT-263Digoxin may decrease the cardiotoxic activities of ABT-263.Investigational
AcarboseThe serum concentration of Digoxin can be decreased when it is combined with Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Digoxin.Approved
AceclofenacThe serum concentration of Digoxin can be increased when it is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Digoxin.Approved
AcetovanilloneThe serum concentration of Digoxin can be increased when it is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Digoxin can be increased when it is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinDigoxin may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideDigoxin may decrease the cardiotoxic activities of Acteoside.Investigational
AdapaleneThe serum concentration of Digoxin can be increased when it is combined with Adapalene.Approved
AdenosineThe risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Digoxin.Approved
AfimoxifeneDigoxin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptDigoxin may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinDigoxin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleDigoxin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinDigoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Digoxin.Experimental
AlectinibThe serum concentration of Digoxin can be increased when it is combined with Alectinib.Approved
AlemtuzumabDigoxin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Digoxin.Approved, Nutraceutical
AlfentanilThe serum concentration of Digoxin can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinDigoxin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Digoxin can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Digoxin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
Alpha-DifluoromethylornithineDigoxin may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
AlprenololAlprenolol may increase the bradycardic activities of Digoxin.Approved, Withdrawn
AltretamineDigoxin may decrease the cardiotoxic activities of Altretamine.Approved
AmantadineThe serum concentration of Digoxin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Digoxin.Approved, Investigational
Amg 386Digoxin may decrease the cardiotoxic activities of Amg 386.Investigational
AmikacinThe serum concentration of Digoxin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Digoxin can be decreased when used in combination with Amiloride.Approved
AminocamptothecinDigoxin may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideDigoxin may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Digoxin can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidDigoxin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Digoxin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Digoxin.Approved
AmlodipineThe serum concentration of Digoxin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Digoxin can be increased when it is combined with Amodiaquine.Approved
AmonafideDigoxin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.Approved, Investigational
AmprenavirThe serum concentration of Digoxin can be increased when it is combined with Amprenavir.Approved
AmrubicinDigoxin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineDigoxin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideDigoxin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleDigoxin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveDigoxin may decrease the cardiotoxic activities of Anecortave.Investigational
AnisodamineThe serum concentration of Digoxin can be increased when it is combined with Anisodamine.Investigational
annamycinDigoxin may decrease the cardiotoxic activities of annamycin.Investigational
AntipyrineThe serum concentration of Digoxin can be increased when it is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Digoxin can be increased when it is combined with Antithrombin III human.Approved
Aop200704Aop200704 may increase the bradycardic activities of Digoxin.Investigational
AP 12009Digoxin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Digoxin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneDigoxin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApixabanThe serum concentration of Digoxin can be increased when it is combined with Apixaban.Approved
ApramycinThe serum concentration of Digoxin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ApremilastThe serum concentration of Digoxin can be increased when it is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Digoxin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Digoxin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbekacinThe serum concentration of Digoxin can be decreased when it is combined with Arbekacin.Approved
ArgatrobanThe serum concentration of Digoxin can be increased when it is combined with Argatroban.Approved, Investigational
ArotinololArotinolol may increase the bradycardic activities of Digoxin.Approved
Arsenic trioxideDigoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ASA404Digoxin may decrease the cardiotoxic activities of ASA404.Investigational
AsparaginaseDigoxin may decrease the cardiotoxic activities of Asparaginase.Approved
AstemizoleThe serum concentration of Digoxin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Digoxin can be increased when it is combined with Asunaprevir.Approved, Investigational
AT-101Digoxin may decrease the cardiotoxic activities of AT-101.Investigational
AtazanavirThe serum concentration of Digoxin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Digoxin.Approved
AtomoxetineThe metabolism of Digoxin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Digoxin can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Digoxin.Approved
AxitinibDigoxin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineDigoxin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzapropazoneThe serum concentration of Digoxin can be increased when it is combined with Azapropazone.Withdrawn
AzathioprineDigoxin may decrease the cardiotoxic activities of Azathioprine.Approved
AZD2171Digoxin may decrease the cardiotoxic activities of AZD2171.Investigational
Azd4547Digoxin may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidDigoxin may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzelastineThe serum concentration of Digoxin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Digoxin can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Digoxin can be increased when it is combined with Balsalazide.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Digoxin.Approved
BatimastatThe serum concentration of Digoxin can be increased when it is combined with Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Digoxin.Experimental
BelinostatDigoxin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanDigoxin may decrease the cardiotoxic activities of Belotecan.Investigational
BenazeprilThe serum concentration of Digoxin can be increased when it is combined with Benazepril.Approved, Investigational
BendamustineDigoxin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin.Approved
BenoxaprofenThe serum concentration of Digoxin can be increased when it is combined with Benoxaprofen.Withdrawn
BenzamidineThe serum concentration of Digoxin can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Digoxin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Digoxin can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantDigoxin may increase the bradycardic activities of Beractant.Approved
BesifloxacinDigoxin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Digoxin.Approved, Vet Approved
BetaxololBetaxolol may increase the bradycardic activities of Digoxin.Approved
Betulinic AcidThe serum concentration of Digoxin can be increased when it is combined with Betulinic Acid.Investigational
BevacizumabDigoxin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Digoxin.Approved
BexaroteneDigoxin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Digoxin may decrease the cardiotoxic activities of Bgj398.Investigational
Bi201335The serum concentration of Digoxin can be increased when it is combined with Bi201335.Investigational
BicalutamideDigoxin may decrease the cardiotoxic activities of Bicalutamide.Approved
BiperidenThe serum concentration of Digoxin can be increased when it is combined with Biperiden.Approved
BisoprololDigoxin may increase the bradycardic activities of Bisoprolol.Approved
BivalirudinThe serum concentration of Digoxin can be increased when it is combined with Bivalirudin.Approved, Investigational
BizelesinDigoxin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinDigoxin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabDigoxin may decrease the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Digoxin may decrease the cardiotoxic activities of Bmn 673.Investigational
BoceprevirThe serum concentration of Digoxin can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the bradycardic activities of Digoxin.Approved
BortezomibDigoxin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosentanThe serum concentration of Digoxin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Digoxin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Digoxin.Approved
BretyliumBretylium may increase the bradycardic activities of Digoxin.Approved
BrimonidineBrimonidine may increase the bradycardic activities of Digoxin.Approved
BromfenacThe serum concentration of Digoxin can be increased when it is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Digoxin.Approved, Investigational
BroxuridineDigoxin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Digoxin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Digoxin may decrease the cardiotoxic activities of BSI-201.Investigational
BucillamineThe serum concentration of Digoxin can be increased when it is combined with Bucillamine.Investigational
BucindololBucindolol may increase the bradycardic activities of Digoxin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Digoxin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.Approved
BupranololBupranolol may increase the bradycardic activities of Digoxin.Approved
BuprenorphineThe serum concentration of Digoxin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Digoxin can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanDigoxin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineDigoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelDigoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineDigoxin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibDigoxin may decrease the cardiotoxic activities of Cabozantinib.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Digoxin.Approved
CaiDigoxin may decrease the cardiotoxic activities of Cai.Investigational
CalcidiolCalcidiol may increase the arrhythmogenic activities of Digoxin.Approved, Nutraceutical
CalcipotriolDigoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Digoxin.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Digoxin.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Digoxin.Approved
Calcium carbonateCalcium carbonate may increase the arrhythmogenic activities of Digoxin.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Digoxin.Approved
Calcium citrateCalcium citrate may increase the arrhythmogenic activities of Digoxin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Digoxin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Digoxin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Digoxin.Approved, Vet Approved
CalfactantDigoxin may increase the bradycardic activities of Calfactant.Approved
CamptothecinDigoxin may decrease the cardiotoxic activities of Camptothecin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Digoxin.Approved
CandesartanThe serum concentration of Digoxin can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Digoxin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Digoxin can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineDigoxin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Digoxin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Digoxin can be increased when combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Digoxin can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Digoxin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinDigoxin may decrease the cardiotoxic activities of Carboplatin.Approved
CarfilzomibDigoxin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurDigoxin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineDigoxin may decrease the cardiotoxic activities of Carmustine.Approved
CarprofenThe serum concentration of Digoxin can be increased when it is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololDigoxin may increase the bradycardic activities of Carteolol.Approved
CarvedilolDigoxin may increase the bradycardic activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Digoxin can be increased when it is combined with Caspofungin.Approved
CastanospermineThe serum concentration of Digoxin can be increased when it is combined with Castanospermine.Experimental
CatumaxomabDigoxin may decrease the cardiotoxic activities of Catumaxomab.Investigational
CB1954Digoxin may decrease the cardiotoxic activities of CB1954.Experimental
CediranibDigoxin may decrease the cardiotoxic activities of Cediranib.Investigational
CelecoxibThe serum concentration of Digoxin can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Digoxin.Approved, Investigational
CeritinibDigoxin may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Digoxin.Withdrawn
CetuximabDigoxin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilDigoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Digoxin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.Approved, Vet Approved
ChlorotrianiseneDigoxin may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Digoxin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Digoxin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Digoxin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Digoxin.Approved, Nutraceutical
CholesterolThe serum concentration of Digoxin can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Digoxin can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Digoxin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Digoxin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Digoxin.Approved
CinoxacinDigoxin may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinDigoxin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Digoxin.Approved
CisplatinDigoxin may decrease the cardiotoxic activities of Cisplatin.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Digoxin.Approved
CladribineDigoxin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Digoxin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Digoxin can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Digoxin.Approved, Illicit
ClofarabineDigoxin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Digoxin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Digoxin.Approved, Investigational
ClomipramineThe serum concentration of Digoxin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.Approved
ClonixinThe serum concentration of Digoxin can be increased when it is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Digoxin.Approved, Nutraceutical
clorarabineDigoxin may decrease the cardiotoxic activities of clorarabine.Investigational
ClotrimazoleThe metabolism of Digoxin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Digoxin.Approved
CobicistatThe metabolism of Digoxin can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Digoxin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Digoxin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Digoxin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Digoxin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Digoxin.Approved
CordycepinDigoxin may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibDigoxin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibDigoxin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminThe serum concentration of Digoxin can be increased when it is combined with Curcumin.Investigational
CyclophosphamideDigoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Digoxin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Digoxin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateDigoxin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineDigoxin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
D-LimoneneThe serum concentration of Digoxin can be increased when it is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.Approved
DabrafenibThe serum concentration of Digoxin can be decreased when it is combined with Dabrafenib.Approved
DacarbazineDigoxin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Digoxin can be increased when it is combined with Daclatasvir.Approved
DactinomycinDigoxin may decrease the cardiotoxic activities of Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Digoxin.Approved
DaratumumabDigoxin may decrease the cardiotoxic activities of Daratumumab.Approved
DarunavirThe serum concentration of Digoxin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Digoxin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDigoxin may decrease the cardiotoxic activities of Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Digoxin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Digoxin.Approved
DecitabineDigoxin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Digoxin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Digoxin can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxDigoxin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinDigoxin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DesipramineThe serum concentration of Digoxin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Digoxin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneDigoxin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDigoxin may increase the bradycardic activities of Dexmedetomidine.Approved, Vet Approved
DexrazoxaneDigoxin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Digoxin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Digoxin.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Digoxin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienogestDigoxin may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolDigoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DiflunisalThe serum concentration of Digoxin can be increased when it is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Digoxin can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinThe serum concentration of Digoxin can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Digoxin.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Digoxin.Illicit
DiindolylmethaneDigoxin may decrease the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemThe metabolism of Digoxin can be decreased when combined with Diltiazem.Approved
DinutuximabDigoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Digoxin.Approved
DocetaxelDigoxin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Digoxin.Experimental
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Digoxin.Approved, Investigational, Vet Approved
DonepezilDigoxin may increase the bradycardic activities of Donepezil.Approved
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Digoxin.Approved
DoxazosinThe serum concentration of Digoxin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Digoxin can be increased when it is combined with Doxepin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Digoxin.Approved
DoxifluridineDigoxin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Digoxin.Approved, Investigational
DoxorubicinDigoxin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Digoxin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Digoxin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneDigoxin may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
DroxicamThe serum concentration of Digoxin can be increased when it is combined with Droxicam.Approved
DuvelisibThe serum concentration of Digoxin can be increased when it is combined with Duvelisib.Investigational
E6201The serum concentration of Digoxin can be increased when it is combined with E6201.Investigational
EbselenThe serum concentration of Digoxin can be increased when it is combined with Ebselen.Investigational
EcabetThe serum concentration of Digoxin can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Digoxin.Approved
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Digoxin.Approved
efaproxiralDigoxin may decrease the cardiotoxic activities of efaproxiral.Investigational
EfavirenzThe serum concentration of Digoxin can be decreased when it is combined with Efavirenz.Approved, Investigational
EflornithineDigoxin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Digoxin may decrease the cardiotoxic activities of EG009.Investigational
ElafinThe serum concentration of Digoxin can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Digoxin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Digoxin.Approved, Investigational
EliglustatThe serum concentration of Digoxin can be increased when it is combined with Eliglustat.Approved
ElsamitrucinDigoxin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EltrombopagThe serum concentration of Digoxin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Digoxin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Digoxin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Digoxin can be increased when it is combined with Enalkiren.Experimental
EndostatinDigoxin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinDigoxin may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinDigoxin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatDigoxin may decrease the cardiotoxic activities of Entinostat.Investigational
EnzalutamideThe serum concentration of Digoxin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Digoxin.Approved, Investigational
EpirizoleThe serum concentration of Digoxin can be increased when it is combined with Epirizole.Approved
EpirubicinDigoxin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Digoxin can be decreased when used in combination with Eplerenone.Approved
EpofolateDigoxin may decrease the cardiotoxic activities of Epofolate.Investigational
EpoprostenolThe serum concentration of Digoxin can be increased when it is combined with Epoprostenol.Approved
Epothilone BDigoxin may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Digoxin.Approved, Nutraceutical
ErgonovineThe serum concentration of Digoxin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Digoxin can be increased when it is combined with Ergotamine.Approved
EribulinDigoxin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibDigoxin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Digoxin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Digoxin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the bradycardic activities of Digoxin.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Digoxin.Approved, Investigational, Vet Approved
EstramustineDigoxin may decrease the cardiotoxic activities of Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Digoxin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Digoxin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.Approved
EtanerceptThe serum concentration of Digoxin can be increased when it is combined with Etanercept.Approved, Investigational
EtanidazoleDigoxin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Digoxin.Approved
Ethiodized oilDigoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateDigoxin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtodolacThe serum concentration of Digoxin can be increased when it is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe serum concentration of Digoxin can be increased when it is combined with Etofenamate.Approved
EtoposideDigoxin may decrease the cardiotoxic activities of Etoposide.Approved
EtoricoxibThe serum concentration of Digoxin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Digoxin can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe serum concentration of Digoxin can be increased when it is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Digoxin.Approved
ExatecanDigoxin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneDigoxin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindThe serum concentration of Digoxin can be increased when it is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Digoxin.Approved
FelodipineThe serum concentration of Digoxin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe serum concentration of Digoxin can be increased when it is combined with Fenbufen.Approved
FenoprofenThe serum concentration of Digoxin can be increased when it is combined with Fenoprofen.Approved
FenretinideDigoxin may decrease the cardiotoxic activities of Fenretinide.Investigational
FentanylThe serum concentration of Digoxin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Digoxin.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Digoxin.Approved
FiacitabineDigoxin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Digoxin.Approved
FingolimodDigoxin may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlavopiridolDigoxin may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FlecainideThe serum concentration of Digoxin can be increased when it is combined with Flecainide.Approved, Withdrawn
FleroxacinDigoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
FlibanserinThe serum concentration of Digoxin can be increased when it is combined with Flibanserin.Approved
FloctafenineThe serum concentration of Digoxin can be increased when it is combined with Floctafenine.Approved, Withdrawn
FloxuridineDigoxin may decrease the cardiotoxic activities of Floxuridine.Approved
FluconazoleThe metabolism of Digoxin can be decreased when combined with Fluconazole.Approved
FludarabineDigoxin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineDigoxin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FlunixinThe serum concentration of Digoxin can be increased when it is combined with Flunixin.Vet Approved
FluorouracilDigoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
FluoxetineThe serum concentration of Digoxin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Digoxin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Digoxin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Digoxin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe serum concentration of Digoxin can be increased when it is combined with Flurbiprofen.Approved, Investigational
FlutamideDigoxin may decrease the cardiotoxic activities of Flutamide.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Digoxin.Approved
FluvoxamineThe metabolism of Digoxin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneDigoxin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinDigoxin may decrease the cardiotoxic activities of Formycin.Experimental
FosamprenavirThe serum concentration of Digoxin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Digoxin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Digoxin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Digoxin can be increased when combined with Fosphenytoin.Approved
FotemustineDigoxin may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Digoxin can be decreased when it is combined with Framycetin.Approved
FulvestrantDigoxin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinDigoxin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Digoxin can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Digoxin can be increased when it is combined with Gabexate.Investigational
GalantamineDigoxin may increase the bradycardic activities of Galantamine.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Digoxin.Approved
Gallium nitrateDigoxin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinDigoxin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinDigoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibDigoxin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinThe serum concentration of Digoxin can be increased when it is combined with Geldanamycin.Experimental
GemcitabineDigoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinDigoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinDigoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinThe serum concentration of Digoxin can be decreased when it is combined with Geneticin.Experimental
GenisteinDigoxin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Digoxin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Digoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CDigoxin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Digoxin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Digoxin can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumThe serum concentration of Digoxin can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GM6001The serum concentration of Digoxin can be increased when it is combined with GM6001.Experimental
GoserelinDigoxin may decrease the cardiotoxic activities of Goserelin.Approved
Gramicidin DThe serum concentration of Digoxin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Digoxin.Approved
GrepafloxacinDigoxin may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GuanfacineDigoxin may increase the bradycardic activities of Guanfacine.Approved, Investigational
GusperimusDigoxin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinDigoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneDigoxin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Digoxin.Approved
HexestrolDigoxin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HigenamineThe serum concentration of Digoxin can be increased when it is combined with Higenamine.Investigational
HirulogThe serum concentration of Digoxin can be increased when it is combined with Hirulog.Experimental
HMPL-004The serum concentration of Digoxin can be increased when it is combined with HMPL-004.Investigational
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Digoxin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin.Approved
HydroxychloroquineThe serum concentration of Digoxin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateDigoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaDigoxin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Digoxin can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibDigoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
IbuprofenThe serum concentration of Digoxin can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe serum concentration of Digoxin can be increased when it is combined with Ibuproxam.Withdrawn
IcatibantThe serum concentration of Digoxin can be increased when it is combined with Icatibant.Approved
IdarubicinDigoxin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Digoxin can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Digoxin can be increased when it is combined with idraparinux.Investigational
IfosfamideDigoxin may decrease the cardiotoxic activities of Ifosfamide.Approved
Il 4Digoxin may decrease the cardiotoxic activities of Il 4.Investigational
ImatinibDigoxin may decrease the cardiotoxic activities of Imatinib.Approved
ImidaprilThe serum concentration of Digoxin can be increased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Digoxin.Approved
ImiquimodDigoxin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Digoxin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.Approved
IndenololIndenolol may increase the bradycardic activities of Digoxin.Withdrawn
IndinavirThe serum concentration of Digoxin can be increased when it is combined with Indinavir.Approved
IndirubinDigoxin may decrease the cardiotoxic activities of Indirubin.Investigational
IndomethacinThe serum concentration of Digoxin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe serum concentration of Digoxin can be increased when it is combined with Indoprofen.Withdrawn
INNO-206The serum concentration of Digoxin can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aDigoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bDigoxin may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneDigoxin may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabDigoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanDigoxin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenDigoxin may decrease the cardiotoxic activities of Irofulven.Investigational
IsavuconazoniumThe serum concentration of Digoxin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Digoxin can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoxicamThe serum concentration of Digoxin can be increased when it is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Digoxin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Digoxin can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineDigoxin may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Digoxin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Digoxin.Approved, Vet Approved
IxabepiloneDigoxin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibThe serum concentration of Digoxin can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Digoxin can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Digoxin can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Digoxin can be decreased when it is combined with Kaolin.Approved
KebuzoneThe serum concentration of Digoxin can be increased when it is combined with Kebuzone.Experimental
KetamineThe serum concentration of Digoxin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Digoxin.Approved
KetoconazoleThe metabolism of Digoxin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Digoxin can be increased when it is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe serum concentration of Digoxin can be increased when it is combined with Ketorolac.Approved
KitasamycinThe serum concentration of Digoxin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Digoxin may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineDigoxin may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolDigoxin may increase the bradycardic activities of Labetalol.Approved
LacosamideDigoxin may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Digoxin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Digoxin.Approved, Investigational
LanreotideDigoxin may decrease the cardiotoxic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Digoxin.Approved, Investigational
LapatinibDigoxin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Digoxin.Approved
LeflunomideThe serum concentration of Digoxin can be increased when it is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Digoxin can be increased when it is combined with Lenalidomide.Approved
LenvatinibDigoxin may decrease the cardiotoxic activities of Lenvatinib.Approved
LepirudinThe serum concentration of Digoxin can be increased when it is combined with Lepirudin.Approved
LetrozoleDigoxin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideDigoxin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Digoxin.Approved, Investigational
LevobunololDigoxin may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinDigoxin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Digoxin.Approved
LevothyroxineThe serum concentration of Digoxin can be decreased when it is combined with Levothyroxine.Approved
LiarozoleDigoxin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Digoxin.Approved
LidocaineThe serum concentration of Digoxin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Digoxin.Approved
LiothyronineThe serum concentration of Digoxin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Digoxin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Digoxin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe serum concentration of Digoxin can be increased when it is combined with Lisofylline.Investigational
LomefloxacinDigoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomitapideThe serum concentration of Digoxin can be increased when it is combined with Lomitapide.Approved
LomustineDigoxin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineDigoxin may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Digoxin.Approved
LopinavirThe serum concentration of Digoxin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Digoxin can be increased when it is combined with Loratadine.Approved
LornoxicamThe serum concentration of Digoxin can be increased when it is combined with Lornoxicam.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Digoxin.Approved
LovastatinThe metabolism of Digoxin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe serum concentration of Digoxin can be increased when it is combined with Loxoprofen.Approved
LucinactantDigoxin may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Digoxin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Digoxin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe serum concentration of Digoxin can be increased when it is combined with Lumiracoxib.Approved, Investigational
Ly2801653Digoxin may decrease the cardiotoxic activities of Ly2801653.Investigational
LycopeneDigoxin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideDigoxin may decrease the cardiotoxic activities of Mafosfamide.Investigational
Magnesium salicylateThe serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Digoxin.Approved, Investigational
MaprotilineThe serum concentration of Digoxin can be increased when it is combined with Maprotiline.Approved
MasitinibDigoxin may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolThe serum concentration of Digoxin can be increased when it is combined with Masoprocol.Approved
MaxacalcitolDigoxin may decrease the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Digoxin may decrease the cardiotoxic activities of MDX-1106.Investigational
MebendazoleDigoxin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineDigoxin may decrease the cardiotoxic activities of Mechlorethamine.Approved
Meclofenamic acidThe serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.Approved, Vet Approved
MedrogestoneDigoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateDigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidThe serum concentration of Digoxin can be increased when it is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Digoxin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateDigoxin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MeloxicamThe serum concentration of Digoxin can be increased when it is combined with Meloxicam.Approved, Vet Approved
MelphalanDigoxin may decrease the cardiotoxic activities of Melphalan.Approved
MeprobamateThe serum concentration of Digoxin can be increased when it is combined with Meprobamate.Approved, Illicit
MequinolDigoxin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineDigoxin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MesalazineThe serum concentration of Digoxin can be increased when it is combined with Mesalazine.Approved
MetamizoleThe serum concentration of Digoxin can be increased when it is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Digoxin can be increased when it is combined with Methadone.Approved
MethimazoleThe serum concentration of Digoxin can be increased when it is combined with Methimazole.Approved
MethotrexateDigoxin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.Approved
Methyl aminolevulinateDigoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethyldopaDigoxin may increase the bradycardic activities of Methyldopa.Approved
MethylprednisoloneDigoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneDigoxin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololDigoxin may increase the bradycardic activities of Metipranolol.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Digoxin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Digoxin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Digoxin.Approved, Investigational
MetrizamideThe serum concentration of Digoxin can be decreased when it is combined with Metrizamide.Approved
MGI-114Digoxin may decrease the cardiotoxic activities of MGI-114.Investigational
MibefradilThe serum concentration of Digoxin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Digoxin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Digoxin.Approved, Illicit
MidodrineDigoxin may increase the bradycardic activities of Midodrine.Approved
MidostaurinDigoxin may decrease the cardiotoxic activities of Midostaurin.Investigational
MifepristoneThe serum concentration of Digoxin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Digoxin.Approved
MiltefosineDigoxin may decrease the cardiotoxic activities of Miltefosine.Approved
MirabegronThe serum concentration of Digoxin can be increased when it is combined with Mirabegron.Approved
MisonidazoleDigoxin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneDigoxin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolDigoxin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinDigoxin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneThe serum concentration of Digoxin can be decreased when it is combined with Mitotane.Approved
MitoxantroneDigoxin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Digoxin.Approved
MizoribineThe serum concentration of Digoxin can be increased when it is combined with Mizoribine.Investigational
MLN576Digoxin may decrease the cardiotoxic activities of MLN576.Investigational
ModafinilThe serum concentration of Digoxin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Digoxin can be increased when it is combined with Moexipril.Approved
MolgramostimDigoxin may decrease the cardiotoxic activities of Molgramostim.Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Digoxin.Approved, Investigational
motexafin gadoliniumDigoxin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinDigoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Digoxin can be increased when it is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Digoxin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneThe serum concentration of Digoxin can be increased when it is combined with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Digoxin.Approved
NafamostatThe serum concentration of Digoxin can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Digoxin can be decreased when it is combined with Nafcillin.Approved
NaftifineThe serum concentration of Digoxin can be increased when it is combined with Naftifine.Approved
Nalidixic AcidDigoxin may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Digoxin.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Digoxin.Approved, Vet Approved
NaltrexoneThe serum concentration of Digoxin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NamitecanDigoxin may decrease the cardiotoxic activities of Namitecan.Investigational
NaproxenThe serum concentration of Digoxin can be increased when it is combined with Naproxen.Approved, Vet Approved
NaringeninThe serum concentration of Digoxin can be increased when it is combined with Naringenin.Experimental
NavitoclaxDigoxin may decrease the cardiotoxic activities of Navitoclax.Investigational
NCX 4016The serum concentration of Digoxin can be increased when it is combined with NCX 4016.Investigational
NeamineThe serum concentration of Digoxin can be decreased when it is combined with Neamine.Experimental
NebivololDigoxin may increase the bradycardic activities of Nebivolol.Approved, Investigational
NecitumumabDigoxin may decrease the cardiotoxic activities of Necitumumab.Approved
NefazodoneThe serum concentration of Digoxin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineDigoxin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Digoxin can be increased when it is combined with Nelfinavir.Approved
NeomycinThe serum concentration of Digoxin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Digoxin.Investigational
NeostigmineThe serum concentration of Digoxin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe serum concentration of Digoxin can be increased when it is combined with Nepafenac.Approved
NetilmicinThe serum concentration of Digoxin can be decreased when it is combined with Netilmicin.Approved
NetupitantThe serum concentration of Digoxin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Digoxin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Digoxin.Approved
NifedipineThe serum concentration of Digoxin can be increased when it is combined with Nifedipine.Approved
Niflumic AcidThe serum concentration of Digoxin can be increased when it is combined with Niflumic Acid.Approved
NiguldipineDigoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibDigoxin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideDigoxin may decrease the cardiotoxic activities of Nilutamide.Approved
NimesulideThe serum concentration of Digoxin can be increased when it is combined with Nimesulide.Approved, Withdrawn
NimustineDigoxin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibDigoxin may decrease the cardiotoxic activities of Nintedanib.Approved
NisoldipineThe serum concentration of Digoxin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Digoxin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Digoxin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Digoxin can be increased when it is combined with Nitroaspirin.Investigational
NivolumabDigoxin may decrease the cardiotoxic activities of Nivolumab.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Digoxin.Approved
Nk012Digoxin may decrease the cardiotoxic activities of Nk012.Investigational
nocodazoleDigoxin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedDigoxin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorethisteroneThe serum concentration of Digoxin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinDigoxin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabDigoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideDigoxin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabDigoxin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinDigoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Digoxin.Approved, Investigational
OlaparibDigoxin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Digoxin can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.Approved
OlsalazineThe serum concentration of Digoxin can be increased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateDigoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OmapatrilatThe serum concentration of Digoxin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Digoxin can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe serum concentration of Digoxin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinDigoxin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OrgoteinThe serum concentration of Digoxin can be increased when it is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Digoxin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Digoxin can be increased when it is combined with Otamixaban.Investigational
OxaliplatinDigoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxaprozinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the bradycardic activities of Digoxin.Approved
OxyphenbutazoneThe serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Digoxin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelDigoxin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Digoxin can be increased when it is combined with Palbociclib.Approved
PalifosfamideDigoxin may decrease the cardiotoxic activities of Palifosfamide.Investigational
Palmitic AcidThe serum concentration of Digoxin can be increased when it is combined with Palmitic Acid.Experimental
PamidronateDigoxin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Digoxin.Approved
PanitumumabDigoxin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatDigoxin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Digoxin can be increased when it is combined with Pantoprazole.Approved
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin.Approved, Investigational
ParecoxibThe serum concentration of Digoxin can be increased when it is combined with Parecoxib.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin.Approved, Investigational
ParitaprevirThe serum concentration of Digoxin can be increased when it is combined with Paritaprevir.Approved
ParomomycinThe serum concentration of Digoxin can be decreased when it is combined with Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Digoxin can be increased when it is combined with Paroxetine.Approved, Investigational
PARP inhibitorDigoxin may decrease the cardiotoxic activities of PARP inhibitor.Investigational
PasireotideDigoxin may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Digoxin.Approved
PazufloxacinDigoxin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinDigoxin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseDigoxin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabDigoxin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedDigoxin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololDigoxin may increase the bradycardic activities of Penbutolol.Approved, Investigational
PenclomedineDigoxin may decrease the cardiotoxic activities of Penclomedine.Investigational
PenicillamineThe serum concentration of Digoxin can be decreased when it is combined with Penicillamine.Approved
PentobarbitalThe metabolism of Digoxin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinDigoxin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Digoxin can be increased when it is combined with Perindopril.Approved
PertuzumabDigoxin may decrease the cardiotoxic activities of Pertuzumab.Approved
PhenobarbitalThe metabolism of Digoxin can be increased when combined with Phenobarbital.Approved
Phenylacetic acidDigoxin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
PhenylbutazoneThe serum concentration of Digoxin can be increased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Digoxin can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Digoxin can be increased when it is combined with Phosphoramidon.Experimental
PimecrolimusThe serum concentration of Digoxin can be increased when it is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Digoxin can be increased when it is combined with Pimozide.Approved
PindololDigoxin may increase the bradycardic activities of Pindolol.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Digoxin.Approved
PipobromanDigoxin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinDigoxin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.Experimental
PirfenidoneThe serum concentration of Digoxin can be increased when it is combined with Pirfenidone.Investigational
PirlindoleDigoxin may decrease the cardiotoxic activities of Pirlindole.Approved
PiroxicamThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Digoxin.Approved
PixantroneDigoxin may decrease the cardiotoxic activities of Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Digoxin can be decreased when it is combined with Platelet Activating Factor.Experimental
PlevitrexedDigoxin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinDigoxin may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxDigoxin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinDigoxin may decrease the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidDigoxin may decrease the cardiotoxic activities of polyacrylic acid.Investigational
Polyethylene glycolThe serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.Approved, Vet Approved
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Digoxin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digoxin.Approved
PomalidomideDigoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibDigoxin may decrease the cardiotoxic activities of Ponatinib.Approved
Poractant alfaDigoxin may increase the bradycardic activities of Poractant alfa.Approved
PorfimerDigoxin may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinDigoxin may decrease the cardiotoxic activities of porfiromycin.Investigational
PosaconazoleThe serum concentration of Digoxin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the bradycardic activities of Digoxin.Approved
PralatrexateDigoxin may decrease the cardiotoxic activities of Pralatrexate.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Digoxin.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Digoxin.Approved
PrednimustineDigoxin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneDigoxin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneDigoxin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Digoxin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Digoxin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Digoxin can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Digoxin can be increased when it is combined with Probenecid.Approved
ProcarbazineDigoxin may decrease the cardiotoxic activities of Procarbazine.Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Digoxin.Approved, Vet Approved
PromethazineThe serum concentration of Digoxin can be increased when it is combined with Promethazine.Approved
PropacetamolThe serum concentration of Digoxin can be increased when it is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Digoxin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Digoxin.Approved, Investigational
PropylthiouracilThe serum concentration of Digoxin can be increased when it is combined with Propylthiouracil.Approved
ProtriptylineThe serum concentration of Digoxin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Digoxin.Approved
PTC299The serum concentration of Digoxin can be increased when it is combined with PTC299.Investigational
Purine RibosideDigoxin may decrease the cardiotoxic activities of Purine Riboside.Experimental
PuromycinDigoxin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Digoxin.Approved, Vet Approved
PyrazoloacridineDigoxin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
Qlt091001Digoxin may decrease the cardiotoxic activities of Qlt091001.Investigational
QuercetinThe serum concentration of Digoxin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Digoxin.Approved
QuinacrineDigoxin may decrease the cardiotoxic activities of Quinacrine.Approved
QuinaprilThe serum concentration of Digoxin can be increased when it is combined with Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin.Approved
QuinidineThe serum concentration of Digoxin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Digoxin can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Digoxin can be increased when it is combined with Racecadotril.Investigational
Radium Ra 223 DichlorideDigoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedDigoxin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamiprilThe serum concentration of Digoxin can be increased when it is combined with Ramipril.Approved
RamucirumabDigoxin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabDigoxin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Digoxin.Approved
RanolazineThe serum concentration of Digoxin can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseDigoxin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Digoxin.Withdrawn
ReboxetineThe serum concentration of Digoxin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Digoxin.Approved
RemikirenThe serum concentration of Digoxin can be increased when it is combined with Remikiren.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.Approved
ResveratrolThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.Experimental, Investigational
Rhodamine 6GDigoxin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Digoxin can be decreased when it is combined with Ribostamycin.Approved
RifabutinThe metabolism of Digoxin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Digoxin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Digoxin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Digoxin.Approved, Investigational
RilpivirineThe serum concentration of Digoxin can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Digoxin.Approved, Investigational
RitonavirThe serum concentration of Digoxin can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabDigoxin may decrease the cardiotoxic activities of Rituximab.Approved
RivaroxabanThe serum concentration of Digoxin can be increased when it is combined with Rivaroxaban.Approved
RivastigmineDigoxin may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RocuroniumRocuronium may increase the arrhythmogenic activities of Digoxin.Approved
RofecoxibThe serum concentration of Digoxin can be increased when it is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Digoxin can be increased when it is combined with Rolapitant.Approved
RomidepsinDigoxin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimDigoxin may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexDigoxin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanDigoxin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibDigoxin may decrease the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Digoxin.Approved
SalicylamideThe serum concentration of Digoxin can be increased when it is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Digoxin can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SalirasibDigoxin may decrease the cardiotoxic activities of Salirasib.Investigational
SalsalateThe serum concentration of Digoxin can be increased when it is combined with Salsalate.Approved
SaquinavirThe serum concentration of Digoxin can be increased when it is combined with Saquinavir.Approved, Investigational
SaracatinibDigoxin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinDigoxin may decrease the cardiotoxic activities of Satraplatin.Investigational
SaxagliptinThe serum concentration of Digoxin can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Digoxin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Digoxin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Digoxin.Approved
SeliciclibDigoxin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibDigoxin may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolDigoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental
SeratrodastThe serum concentration of Digoxin can be increased when it is combined with Seratrodast.Approved, Investigational
SertralineThe serum concentration of Digoxin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Digoxin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Digoxin.Approved
SiltuximabThe serum concentration of Digoxin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Digoxin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Digoxin can be increased when it is combined with Simvastatin.Approved
SirolimusDigoxin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Digoxin can be decreased when it is combined with Sisomicin.Investigational
SitagliptinThe serum concentration of Digoxin can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium phenylbutyrateDigoxin may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Digoxin.Approved
SolithromycinThe serum concentration of Digoxin can be increased when it is combined with Solithromycin.Investigational
SonidegibDigoxin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanDigoxin may decrease the cardiotoxic activities of Sonifilan.Investigational
SorafenibDigoxin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolDigoxin may increase the bradycardic activities of Sotalol.Approved
SP1049CThe serum concentration of Digoxin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinDigoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidDigoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinDigoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Digoxin can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Digoxin.Experimental
SpiramycinThe serum concentration of Digoxin can be increased when it is combined with Spiramycin.Approved
SpiraprilThe serum concentration of Digoxin can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Digoxin can be increased when it is combined with Spironolactone.Approved
squalamineDigoxin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501The serum concentration of Digoxin can be increased when it is combined with SRT501.Investigational
St. John's WortThe serum concentration of Digoxin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Digoxin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Digoxin can be increased when it is combined with Stiripentol.Approved
StreptomycinThe serum concentration of Digoxin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinDigoxin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Digoxin.Approved
SucralfateThe serum concentration of Digoxin can be decreased when it is combined with Sucralfate.Approved
SufentanilDigoxin may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineThe serum concentration of Digoxin can be increased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Digoxin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Digoxin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneDigoxin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacThe serum concentration of Digoxin can be increased when it is combined with Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.Approved
SumatriptanThe serum concentration of Digoxin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibDigoxin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuprofenThe serum concentration of Digoxin can be increased when it is combined with Suprofen.Approved, Withdrawn
SuraminDigoxin may decrease the cardiotoxic activities of Suramin.Approved
SwainsonineDigoxin may decrease the cardiotoxic activities of Swainsonine.Experimental
TacrineThe serum concentration of Digoxin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Digoxin.Approved, Investigational
TalaporfinDigoxin may decrease the cardiotoxic activities of Talaporfin.Investigational
TamoxifenDigoxin may decrease the cardiotoxic activities of Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Digoxin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Digoxin.Approved
TegafurDigoxin may decrease the cardiotoxic activities of Tegafur.Approved
TelaprevirThe serum concentration of Digoxin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Digoxin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Digoxin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinDigoxin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemocaprilThe serum concentration of Digoxin can be increased when it is combined with Temocapril.Experimental, Investigational
TemoporfinDigoxin may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideDigoxin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusDigoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideDigoxin may decrease the cardiotoxic activities of Teniposide.Approved
TenoxicamThe serum concentration of Digoxin can be increased when it is combined with Tenoxicam.Approved
TepoxalinThe serum concentration of Digoxin can be increased when it is combined with Tepoxalin.Vet Approved
TerazosinThe serum concentration of Digoxin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Digoxin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Digoxin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Digoxin can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneDigoxin may decrease the cardiotoxic activities of Testolactone.Approved
TestosteroneThe serum concentration of Digoxin can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateDigoxin may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineDigoxin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideDigoxin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiorphanThe serum concentration of Digoxin can be increased when it is combined with Thiorphan.Experimental
ThiotepaDigoxin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinDigoxin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
Tiaprofenic acidThe serum concentration of Digoxin can be increased when it is combined with Tiaprofenic acid.Approved
TiboloneDigoxin may decrease the cardiotoxic activities of Tibolone.Approved
TicagrelorThe serum concentration of Digoxin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Digoxin can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Digoxin.Approved
TinoridineThe serum concentration of Digoxin can be increased when it is combined with Tinoridine.Investigational
TioguanineDigoxin may decrease the cardiotoxic activities of Tioguanine.Approved
TipifarnibDigoxin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TipranavirThe serum concentration of Digoxin can be increased when it is combined with Tipranavir.Approved, Investigational
TirapazamineDigoxin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibDigoxin may decrease the cardiotoxic activities of Tivozanib.Investigational
TizanidineDigoxin may increase the bradycardic activities of Tizanidine.Approved
Tnp 470Digoxin may decrease the cardiotoxic activities of Tnp 470.Investigational
TobramycinThe serum concentration of Digoxin can be decreased when it is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Digoxin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Digoxin.Approved, Investigational
Tolfenamic AcidThe serum concentration of Digoxin can be increased when it is combined with Tolfenamic Acid.Approved
TolmetinThe serum concentration of Digoxin can be increased when it is combined with Tolmetin.Approved
TolvaptanThe serum concentration of Digoxin can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Digoxin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.Approved
ToremifeneDigoxin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabDigoxin may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinDigoxin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibDigoxin may decrease the cardiotoxic activities of Trametinib.Approved
TrandolaprilThe serum concentration of Digoxin can be increased when it is combined with Trandolapril.Approved
TranilastThe serum concentration of Digoxin can be increased when it is combined with Tranilast.Approved, Investigational
TrastuzumabDigoxin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineDigoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Digoxin can be decreased when it is combined with Trazodone.Approved, Investigational
TreosulfanDigoxin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarDigoxin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinDigoxin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Digoxin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Digoxin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineDigoxin may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneDigoxin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Digoxin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateDigoxin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Digoxin can be increased when it is combined with Trimipramine.Approved
TriptorelinDigoxin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
Trisalicylate-cholineThe serum concentration of Digoxin can be increased when it is combined with Trisalicylate-choline.Approved
TrofosfamideDigoxin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TroleandomycinThe serum concentration of Digoxin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinDigoxin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineDigoxin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBDigoxin may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinDigoxin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Digoxin.Approved
TylosinThe serum concentration of Digoxin can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Digoxin can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Digoxin can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Digoxin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Digoxin.Approved
Uracil mustardDigoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanDigoxin may decrease the cardiotoxic activities of Vadimezan.Investigational
Val 083Digoxin may decrease the cardiotoxic activities of Val 083.Investigational
ValdecoxibThe serum concentration of Digoxin can be increased when it is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinDigoxin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibThe serum concentration of Digoxin can be increased when it is combined with Vandetanib.Approved
VapreotideDigoxin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Digoxin.Approved
VeliparibDigoxin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibThe serum concentration of Digoxin can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Digoxin.Approved
VenlafaxineThe metabolism of Digoxin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Digoxin can be decreased when combined with Verapamil.Approved
VerteporfinDigoxin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneDigoxin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VilazodoneThe serum concentration of Digoxin can be increased when it is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Digoxin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineDigoxin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Digoxin.Approved, Investigational
VincristineDigoxin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineDigoxin may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineDigoxin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineDigoxin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideDigoxin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibDigoxin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin ADigoxin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Digoxin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatDigoxin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
XimelagatranThe serum concentration of Digoxin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Ym150The serum concentration of Digoxin can be increased when it is combined with Ym150.Investigational
ZaltoprofenThe serum concentration of Digoxin can be increased when it is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Digoxin.Approved
ZileutonThe serum concentration of Digoxin can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Digoxin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Digoxin can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Digoxin can be increased when it is combined with Zomepirac.Withdrawn
ZorubicinDigoxin may decrease the cardiotoxic activities of Zorubicin.Experimental
Food Interactions
  • Avoid avocado.
  • Avoid bran and high fiber foods within 2 hours of taking this medication.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid salt substitutes containing potassium.
  • Limit garlic, ginger, gingko, and horse chestnut.
References
Synthesis Reference

Wolfgang Voigtlander, Fritz Kaiser, Wolfgang Schaumann, Kurt Stach, “Preparation of C22-alkyl derivative of digoxin.” U.S. Patent US3981862, issued October, 1972.

US3981862
General References
  1. Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45. [PubMed:8094898 ]
  2. Doering W, Konig E, Sturm W: [Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)]. Z Kardiol. 1977 Mar;66(3):121-8. [PubMed:857452 ]
  3. Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88. [PubMed:6665298 ]
  4. Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. [PubMed:15554746 ]
External Links
ATC CodesC01AA05
AHFS Codes
  • 24:04.08
  • 80:04.00
PDB EntriesNot Available
FDA labelDownload (563 KB)
MSDSDownload (74.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.941
Blood Brain Barrier-0.7241
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8586
P-glycoprotein inhibitor INon-inhibitor0.5325
P-glycoprotein inhibitor IINon-inhibitor0.6209
Renal organic cation transporterNon-inhibitor0.8621
CYP450 2C9 substrateNon-substrate0.855
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateNon-inhibitor0.9261
CYP450 2C9 inhibitorNon-inhibitor0.9196
CYP450 2D6 inhibitorNon-inhibitor0.9359
CYP450 2C19 inhibitorNon-inhibitor0.9385
CYP450 3A4 inhibitorNon-inhibitor0.9279
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.9668
BiodegradationNot ready biodegradable0.9555
Rat acute toxicity4.4721 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Inhibitor0.8051
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
  • Roxane laboratories inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Sandoz canada inc
  • Wyeth ayerst laboratories
  • Actavis totowa llc
  • Caraco pharmaceutical laboratories ltd
  • Impax laboratories inc
  • Jerome stevens pharmaceuticals inc
  • West ward pharmaceutical corp
  • Smithkline beecham corp dba glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
TabletOral0.0625 mg
TabletOral0.125 mg
TabletOral0.25 mg
TabletOral.125 mg/1
TabletOral.25 mg/1
TabletOral125 ug/1
TabletOral250 ug/1
InjectionIntramuscular; Intravenous.25 mg/mL
InjectionIntramuscular; Intravenous250 ug/mL
Injection, solutionIntramuscular; Intravenous; Parenteral250 ug/mL
SolutionOral.05 mg/mL
TabletOral.125 mg/301
TabletOral.25 mg/301
LiquidIntramuscular; Intravenous0.25 mg
Injection, solutionIntramuscular; Intravenous100 ug/mL
Injection, solutionIntramuscular; Intravenous250 ug/mL
TabletOral.0625 mg/1
TabletOral.1875 mg/1
LiquidOral.05 mg
LiquidIntramuscular; Intravenous.05 mg
LiquidIntramuscular; Intravenous.25 mg
TabletOral.0625 mg
TabletOral.125 mg
TabletOral.25 mg
LiquidIntramuscular; Intravenous0.05 mg
SolutionOral0.05 mg
TabletOral0.250 mg
Prices
Unit descriptionCostUnit
Digibind 38 mg vial727.91USD vial
Digifab 40 mg vial615.6USD vial
Digoxin powder450.28USD g
Digoxin 0.05 mg/ml Solution 60ml Bottle36.99USD bottle
Lanoxin ped 0.1 mg/ml ampul6.91USD ml
Digoxin Pediatric 0.05 mg/ml6.79USD ml
Digoxin 0.25 mg/ml2.91USD ml
Lanoxin 0.25 mg/ml ampul1.44USD ml
Lanoxin 0.125 mg tablet0.73USD tablet
Lanoxin 0.25 mg tablet0.66USD tablet
Digoxin 0.125 mg tablet0.64USD tablet
Digoxin 0.25 mg tablet0.62USD tablet
Digoxin 0.25 mg/ml ampul0.61USD ml
Lanoxin Pediatric 0.05 mg/ml Elixir0.41USD ml
Lanoxicaps 0.1 mg capsule0.4USD capsule
Lanoxin 125 mcg tablet0.3USD tablet
Lanoxin 250 mcg tablet0.3USD tablet
Digitek 125 mcg tablet0.28USD tablet
Digitek 250 mcg tablet0.28USD tablet
Lanoxicaps 0.05 mg capsule0.28USD capsule
Toloxin 0.0625 mg Tablet0.27USD tablet
Toloxin 0.125 mg Tablet0.27USD tablet
Toloxin 0.25 mg Tablet0.27USD tablet
Digoxin 125 mcg tablet0.22USD tablet
Digoxin 250 mcg tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point217-221Stoll, A .and Kreis, W.; US.Patent 2,776,963; January 8,1957;assigned to Sandoz, AG, Switzerland.
water solubility64.8 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.26SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.127 mg/mLALOGPS
logP1.04ALOGPS
logP2.37ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)7.15ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area203.06 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity193.23 m3·mol-1ChemAxon
Polarizability84.8 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • 12-hydroxysteroid
  • Oxane
  • Saccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA: Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol. 2000 May;38(5):438-46. [PubMed:11272406 ]
  2. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248 ]
  3. Ke YS, Liu ZF, Yang H, Yang T, Huang JS, Rui SB, Cheng GH, Wang YX: Effect of anti-digoxin antiserum on endoxin and membrane ATPase activity in hypoxia-reoxygenation induced myocardial injury. Acta Pharmacol Sin. 2000 Apr;21(4):345-7. [PubMed:11324464 ]
  4. Kumar AR, Kurup PA: A hypothalamic digoxin mediated model for conscious and subliminal perception. J Neural Transm (Vienna). 2001;108(7):855-68. [PubMed:11515751 ]
  5. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A: Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13420-4. Epub 2001 Oct 30. [PubMed:11687608 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248 ]
  2. Wang SW, Pu HF, Kan SF, Tseng CI, Lo MJ, Wang PS: Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells. Br J Pharmacol. 2004 Aug;142(7):1123-30. Epub 2004 Jul 12. [PubMed:15249423 ]
  3. Lin H, Wang SW, Tsai SC, Chen JJ, Chiao YC, Lu CC, Huang WJ, Wang GJ, Chen CF, Wang PS: Inhibitory effect of digoxin on testosterone secretion through mechanisms involving decreases of cyclic AMP production and cytochrome P450scc activity in rat testicular interstitial cells. Br J Pharmacol. 1998 Dec;125(8):1635-40. [PubMed:9886754 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun. 2002 Mar 22;292(1):190-4. [PubMed:11890691 ]
  2. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 2003 Jun 20;306(1):116-20. [PubMed:12788075 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169 ]
  5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  7. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010 ]
  8. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  9. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039 ]
  10. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75. [PubMed:14706813 ]
  11. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120 ]
  12. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552-7. [PubMed:9927403 ]
  13. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700 ]
  14. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  15. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316 ]
  16. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
  17. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  2. Noe B, Hagenbuch B, Stieger B, Meier PJ: Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10346-50. [PubMed:9294213 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids.
Gene Name:
SLC51A
Uniprot ID:
Q86UW1
Molecular Weight:
37734.575 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafficking and stability activities.
Gene Name:
SLC51B
Uniprot ID:
Q86UW2
Molecular Weight:
14346.195 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
Gene Name:
SLCO4A1
Uniprot ID:
Q96BD0
Molecular Weight:
77192.505 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, Hagenbuch B: Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta. 2002 Aug 19;1564(1):183-8. [PubMed:12101011 ]
  2. Dagenais C, Ducharme J, Pollack GM: Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett. 2001 Apr 6;301(3):155-8. [PubMed:11257421 ]
  3. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557 ]
  4. Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA: Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol. 2001 Jun;34(6):881-7. [PubMed:11451172 ]
  5. Gao B, Wenzel A, Grimm C, Vavricka SR, Benke D, Meier PJ, Reme CE: Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2002 Feb;43(2):510-4. [PubMed:11818398 ]
  6. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23